258 related articles for article (PubMed ID: 15938665)
1. Methylphenidate HCl: therapy for attention deficit hyperactivity disorder.
Capp PK; Pearl PL; Conlon C
Expert Rev Neurother; 2005 May; 5(3):325-31. PubMed ID: 15938665
[TBL] [Abstract][Full Text] [Related]
2. Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.
McGough JJ; Pataki CS; Suddath R
Expert Rev Neurother; 2005 Jul; 5(4):437-41. PubMed ID: 16026226
[TBL] [Abstract][Full Text] [Related]
3. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
Wilens TE
J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
[TBL] [Abstract][Full Text] [Related]
4. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
[TBL] [Abstract][Full Text] [Related]
5. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
6. New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder.
Patrick KS; González MA; Straughn AB; Markowitz JS
Expert Opin Drug Deliv; 2005 Jan; 2(1):121-43. PubMed ID: 16296740
[TBL] [Abstract][Full Text] [Related]
7. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder.
Volkow ND; Wang GJ; Fowler JS; Ding YS
Biol Psychiatry; 2005 Jun; 57(11):1410-5. PubMed ID: 15950015
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy of attention-deficit hyperactivity disorder in children and adolescents: update on new stimulant preparations, atomoxetine, and novel treatments.
Prince JB
Child Adolesc Psychiatr Clin N Am; 2006 Jan; 15(1):13-50. PubMed ID: 16321724
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
[TBL] [Abstract][Full Text] [Related]
10. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
Steele M; Weiss M; Swanson J; Wang J; Prinzo RS; Binder CE
Can J Clin Pharmacol; 2006; 13(1):e50-62. PubMed ID: 16456216
[TBL] [Abstract][Full Text] [Related]
11. Single-dose pharmacokinetics of multilayer-release methylphenidate and immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
Quinn D; Bode T; Reiz JL; Donnelly GA; Darke AC
J Clin Pharmacol; 2007 Jun; 47(6):760-6. PubMed ID: 17395894
[TBL] [Abstract][Full Text] [Related]
12. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
13. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M
Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
Lee SI; Hong SD; Kim SY; Kim EJ; Kim JH; Kim JH; Park MK; Park S; Park JH; Oh EY; Lim TS; Cheong S; Cho IH; Choi JW
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):210-6. PubMed ID: 17046131
[TBL] [Abstract][Full Text] [Related]
15. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system.
Heal DJ; Pierce DM
CNS Drugs; 2006; 20(9):713-38. PubMed ID: 16953648
[TBL] [Abstract][Full Text] [Related]
16. Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update.
Prince J
J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S39-45. PubMed ID: 18480676
[TBL] [Abstract][Full Text] [Related]
17. Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter?
Markowitz JS; Patrick KS
J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S54-61. PubMed ID: 18480678
[TBL] [Abstract][Full Text] [Related]
18. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder.
Marcus SC; Wan GJ; Kemner JE; Olfson M
Arch Pediatr Adolesc Med; 2005 Jun; 159(6):572-8. PubMed ID: 15939858
[TBL] [Abstract][Full Text] [Related]
19. Effects of methylphenidate on leptin and appetite in children with attention-deficit hyperactivity disorder: an open label trial.
Işeri E; Kiliç BG; Senol S; Karabacak NI
Methods Find Exp Clin Pharmacol; 2007; 29(1):47-52. PubMed ID: 17344944
[TBL] [Abstract][Full Text] [Related]
20. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.
Findling RL; Wigal SB; Bukstein OG; Boellner SW; Abikoff HB; Turnbow JM; Civil R
Clin Ther; 2009 Aug; 31(8):1844-55. PubMed ID: 19808143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
